Liza

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Liza

Property Description
Active ingredient Drospirenone and Ethinyl Estradiol
Form Oral, Film-coated tablet
Pharmacological class Progestogen-Estrogen Combination
Common use Contraception (Pregnancy Prevention)
Origin Synthetic Formulation

Liza is a prescription-only, synthetic Combined Hormonal Contraceptive (CHC) that is primarily used for pregnancy prevention, delivered as an oral, film-coated tablet. It belongs to the pharmacological class of Progestogen-Estrogen Combinations. This medicine provides a systemic method of reproductive regulation by utilizing a dual-hormone strategy, a concept recognized within the field of pharmacology and family planning.


What is the Drug Class and Composition of Liza?

Liza is classified as a Combined Hormonal Contraceptive because it integrates two distinct, synthetic steroid hormones: an estrogen and a progestogen. The active ingredients are Drospirenone and Ethinyl Estradiol. The structural composition of Drospirenone is chemically related to spironolactone, which gives it characteristic antiandrogenic and mineralocorticoid antagonist properties. This specific synthetic formulation distinguishes the medication from combination pills containing different progestogens, offering a particular type of hormonal balance for its regulatory benefits.


What is the General Purpose of Liza?

The general, primary purpose of Liza is to provide effective, systemic Contraception. This goal is achieved through the complementary action of its two hormones, which interrupt the necessary steps for conception. The fundamental strategy involves the suppression of ovulation, thereby preventing the monthly release of an egg from the ovary. Furthermore, the drug alters the reproductive environment by causing the cervical mucus to thicken and modifying the uterine lining. Combination hormonal contraceptives are a reliable method for preventing pregnancy.

What side effects are possible with Liza?

Possible Side Effects and Safety Information

The following information on possible side effects and safety restrictions is based strictly on official governmental regulatory documents.


Safety Classifications and Restrictions

Contraindications (Do Not Use):

  • Pediatric Patients Under 2 Years of Age: The medicine is strictly forbidden for use in children under 2 years old due to a critical risk of severe, life-threatening dehydration.
  • Mechanical Gastrointestinal Obstruction: The medicine is contraindicated in patients with a known or suspected blockage in the stomach or intestine.

Serious Adverse Reactions:

Severe diarrhea has been reported and is considered a serious adverse reaction. This condition may be associated with dehydration, dizziness, syncope (fainting), and electrolyte abnormalities such as low potassium (hypokalemia).


Frequency of Adverse Reactions

The majority of documented side effects involve the gastrointestinal system and are organized by their frequency in clinical trials, using the standard regulatory classification system (e.g., Very Common ge 1/10, Common ge 1/100 to < 1/10).

Classification System-Organ Class Specific Adverse Reactions
Very Common Gastrointestinal disorders Diarrhea (most frequent adverse reaction)
Common Gastrointestinal disorders Abdominal pain, flatulence, abdominal distension
Common Infections and Infestations Upper respiratory tract infection, viral gastroenteritis
Common Nervous system disorders Headache, dizziness

Most cases of diarrhea were reported as mild or moderate in intensity. Diarrhea often begins early in the course of treatment, typically within the first two weeks.

Other Documented Reactions

Less common adverse events include vomiting, fecal incontinence, and symptoms of dehydration. Hypersensitivity reactions, including rash, hives (urticaria), and angioedema (swelling), have been identified through post-marketing surveillance.

Cautions in Specific Populations: The drug should be used with additional caution in elderly patients or patients with conditions that predispose them to disturbances in water or electrolyte balance, such as cardiovascular diseases or diabetes.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with the combined hormonal contraceptive Liza (Drospirenone and Ethinyl Estradiol) is generally not anticipated to lead to serious adverse effects based on regulatory documentation. However, due to potential complications and the absence of a specific antidote, immediate medical evaluation is required for all suspected cases.

Documented Overdose Presentations

The officially documented clinical signs of acute overdose are typically limited to:

  • Nausea and vomiting (gastrointestinal manifestations).
  • Withdrawal bleeding (or breakthrough bleeding), a hormonal effect particularly noted in females.

Emergency Actions and Required Monitoring

Immediate medical attention must be sought for any suspected overdose. The official management approach is symptomatic and supportive treatment because no specific reversal agent or antidote is known for this medication.

A crucial population-specific concern is the theoretical risk of hyperkalaemia (elevated potassium levels) linked to the drospirenone component’s anti-mineralocorticoid activity. Due to this risk, particularly in patients with pre-existing renal impairment, the medical response may require monitoring of serum electrolytes to prevent severe physiological outcomes.

Therapeutic Uses of Liza

Liza is used in situations involving certain distressing symptoms and applied across domains where additional symptomatic support is needed. Similar medications are relevant for a range of uses, including the management of pain and fever.

Liza is commonly used across conditions presenting with systemic or localized discomfort, including fever, headache, body aches, and pain associated with inflammation. It is generally relevant for easing symptoms that may become intense or disruptive due to conditions involving acute or episodic changes. In these scenarios, the medication provides supportive relief when symptoms interfere with routine activities, supports the patient during difficult episodes by easing distress.

“Liza is applied in clinical settings that involve acute or unstable symptom patterns, supporting the patient during difficult episodes by easing distress.”

Quick Fact: Relief for Pain and Fever

Liza is considered relevant for easing symptoms related to inflammatory or irritative states and supports the patient during episodes of heightened systemic burden. It assists with maintaining functional stability when symptoms escalate temporarily.

Regulatory References

  1. NIH MedlinePlus overview on Ibuprofen

Eligibility and Restrictions for Use

Who can and cannot use Liza?

This section outlines the official population eligibility criteria for Liza (Drospirenone and Ethinyl Estradiol) as defined in regulatory documents. Eligibility is restricted based on age, lifestyle factors, and specific health conditions.

Populations Allowed and Not Allowed

Classification Population Status Regulatory Rule
Allowed Females of reproductive age who have reached menarche and are seeking Contraception Approved use for pregnancy prevention [Source 1.2]
Not Recommended Females who are breastfeeding May reduce milk production; label suggests starting use no earlier than four weeks after delivery [Source 1.2]
Contraindicated Pregnancy (Known or suspected) Use must be discontinued if pregnancy occurs [Source 1.4]

Absolute Contraindications

Liza is contraindicated and must not be used in the following populations due to the risk of serious adverse events, as stated in official labeling:

  • Females who are 35 years of age or older and smoke [Source 1.2].
  • Individuals with a history of, or current, arterial or venous thrombotic diseases (e.g., deep vein thrombosis, stroke, myocardial infarction) [Source 1.3].
  • Patients with active liver disease or the presence of liver tumors [Source 1.1].
  • Patients diagnosed with adrenal insufficiency or renal impairment (kidney disease) [Source 1.1, 4.1].
  • Presence or history of hormone-sensitive cancers, such as breast cancer [Source 1.1, 2.1].
  • History of migraine with focal aura or undiagnosed abnormal uterine bleeding [Source 1.4].

Conditional Use and Age Rules

  • Pediatric Use: Use is not indicated in females who have not yet reached menarche [Source 1.2].
  • Conditional Restriction: The medicine must be discontinued at least four weeks before and for two weeks after major surgery or prolonged immobilization to reduce the risk of thromboembolism [Source 1.2].
  • Conditional Monitoring: Patients on long-term treatment with medications that may increase serum potassium require monitoring during the first cycle of Liza due to the anti-mineralocorticoid activity of drospirenone [Source 4.3].

What should I know about interactions with other medicines?

Liza’s official interaction profile is defined by two primary concerns: the risk of toxicity and the potential for reduced efficacy. This information is based strictly on regulatory documents.

Contraindicated Combinations

  • Co-administration with Hepatitis C drug regimens containing Ombitasvir/Paritaprevir/Ritonavir with or without Dasabuvir is formally contraindicated due to the potential for significant liver enzyme elevations.
  • Use is formally contraindicated in females over 35 years of age who smoke. This substance interaction substantially increases the risk of serious cardiovascular events, including thrombosis.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substances (Examples) Regulatory Outcome
Efficacy Reduction Strong CYP enzyme inducers (e.g., Rifampicin) Increases clearance of the contraceptive hormones, potentially reducing effectiveness.
Increased Exposure Risk Strong CYP3A4 inhibitors (e.g., Ketoconazole) Increases the plasma concentration of Drospirenone by inhibiting its metabolism.
Hyperkalemia Risk Potassium-increasing drugs (e.g., ACE Inhibitors, Potassium-sparing Diuretics, long-term NSAIDs) Increases the risk of hyperkalemia due to Drospirenone’s anti-mineralocorticoid activity.

Liza also reduces the plasma exposure of certain co-administered drugs, such as Lamotrigine, by inducing their metabolism. Furthermore, ingestion of Grapefruit Juice is documented to increase the systemic exposure of Ethinyl Estradiol.

Mechanism of Action

Liza functions as a reversible competitive inhibitor of the enzyme HMG-CoA reductase, the rate-limiting step in the mevalonate pathway. This enzyme is predominantly expressed within the endoplasmic reticulum of hepatocytes. By binding to the active site, Liza blocks the conversion of beta-hydroxy beta-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate.

The resulting reduction in the endogenous intracellular concentration of cholesterol triggers a compensatory cellular response. This involves the activation of sterol regulatory element-binding proteins (SREBPs), which translocate to the nucleus and increase the transcriptional expression of genes encoding the LDL receptor on the hepatocyte surface. The enhanced density of hepatic LDL receptors facilitates increased clearance of low-density lipoprotein (LDL) particles from the systemic circulation via receptor-mediated endocytosis, leading to a modulation of the overall plasma lipid profile.

Dosage and Administration Information

How to Use Liza: Official Administration Guidelines

Liza (Drospirenone 3 mg/Ethinyl Estradiol 0.02 mg) is administered solely through the oral route as a film-coated tablet. The official usage protocol is structured around a continuous 28-day cyclic regimen. The regimen mandates one tablet be taken daily at the same time each day to maintain consistent hormonal levels.

Dosing and Schedule Structure

The 28-day cycle consists of two distinct phases. The first phase requires the sequential administration of 24 active tablets, each containing the specified hormone doses. This is immediately followed by 4 inert tablets, which are hormone-free, concluding the cycle. The tablets must be swallowed whole in the order directed on the blister pack, as this ensures the correct daily progression of the hormone dose.

Instruction Category Official Guideline
Route of administration Oral (taken by mouth)
Dosing schedule One tablet daily (24 active / 4 inert)
Timing condition May be taken with or without food

Administration Context and Procedural Rules

While the timing relative to meals is flexible, the requirement for taking the tablet at the same time every day is a key administration principle. The medicine is indicated for use in females who have achieved menarche. If the initial cycle is started late, or if active tablets are missed during the course, specific procedural rules must be followed, including conditions under which a non-hormonal back-up method is required. A new 28-day pack must be started the day immediately following the last tablet of the previous cycle.

Recent Clinical Evidence

Liza, which has the active substance mirabegron, is a beta-3 adrenergic receptor agonist investigated for the management of overactive bladder (OAB) symptoms.


Efficacy and Clinical Outcomes

Phase 3 randomized, double-blind, placebo-controlled clinical trials consistently report that mirabegron is associated with statistically significant improvements in OAB symptoms. These studies, which compared the drug to placebo, measured changes in key endpoints such as the mean number of micturitions per 24 hours and the mean number of urinary incontinence episodes per 24 hours. Meta-analyses of these trials indicate that measured improvements in these symptoms are typically observed within four to eight weeks of initiating treatment.

Research has also explored the use of mirabegron in combination with antimuscarinic medications. Findings suggest that combination therapy may be an option for patients who experience an inadequate response to monotherapy with either agent alone, demonstrating consistent improvements in urinary frequency and incontinence compared to monotherapy.


Pharmacokinetic Profile

Mirabegron is administered once daily, with steady-state concentrations generally achieved after approximately seven days. Peak plasma concentration ( Cmax) occurs around 3.5 hours after oral administration. The drug is metabolized in the liver by multiple enzyme systems, including CYP3A4 and CYP2D6. Its terminal elimination half-life is approximately 50 hours in adults, with excretion occurring through both urine and feces.

Frequently Asked Questions (FAQ)

Common questions about Liza (FAQ)


Q: What should I do if I forget to use Liza?

Official product information outlines specific procedural rules for handling missed doses, and these rules vary depending on how many active tablets were missed and during which week of the cycle. Missing active pills can increase the risk of pregnancy, and a non-hormonal back-up method of contraception may be required. It is important to consult the patient information leaflet or a healthcare provider for the specific rules that apply.


Q: Can Liza cause long-term problems?

Regulatory documents include warnings about the potential for serious cardiovascular events, which include blood clots (thromboembolism), stroke, and heart attack. This risk is notably increased for women over 35 years old who smoke. Other documented risks mentioned are high blood pressure and rare issues like liver tumors.


Q: What are the most common side effects listed in official sources for Liza?

Official clinical trial data indicates that the most frequently reported adverse reactions include headache/migraine, menstrual irregularities (bleeding/spotting), nausea/vomiting, breast pain or tenderness, and some mood changes.


Q: How long do the effects of Liza usually last?

The medicine is designed for continuous action through daily use. The major active component, drospirenone, has a terminal half-life of approximately 31 hours. This half-life influences the requirement for the medication to be taken daily to maintain continuous hormonal levels.


Q: How does Liza compare to a placebo in clinical trials?

Clinical trials, including placebo-controlled studies, established the drug's effectiveness for its approved uses. Official product information states that the medicine has indications for preventing pregnancy, and treating symptoms of PMDD (Premenstrual Dysphoric Disorder) and moderate acne in women who choose an oral contraceptive.


Q: What are the signs of a serious, but rare, interaction involving Liza?

Symptoms that may be associated with a serious event, as outlined in official warnings, warrant immediate medical attention. These may include signs of a blood clot like sudden, severe chest pain or leg pain, severe headache, jaundice (yellowing of the skin/eyes), or pain/tenderness in the upper stomach.


Q: What are the ingredients in Liza besides the active one?

The product is composed of 24 active tablets containing the hormones and 4 inert tablets (placebos). The tablets also contain several inactive ingredients (excipients) such as lactose monohydrate, corn starch, and magnesium stearate, which are listed in the full product description.


Q: What did the main clinical trials on Liza study?

The primary clinical trials investigated the medicine's effectiveness for three specific purposes: prevention of pregnancy, treating moderate acne, and managing symptoms associated with Premenstrual Dysphoric Disorder (PMDD) in women who are seeking an oral contraceptive.


Q: If I am taking a blood thinner, is Liza still an option?

Official labeling states this medicine is contraindicated (should not be used) in women with a high risk of blood clots or those with current or past thrombotic diseases. This scenario requires evaluation by a healthcare provider to assess the individual risk.


Q: What are the requirements for a doctor to prescribe Liza?

Official guidance states that healthcare providers should assess the patient's individual risk for venous thromboembolism (VTE), which is the risk of blood clots, before prescribing. They are also required to monitor serum potassium in certain high-risk patients during the first cycle of use.


Q: What are the reasons someone might need to change from Liza to another drug?

Official labeling states the medicine must be stopped if a serious event occurs (such as jaundice or a blood clot) or if the user develops a contraindication (like uncontrolled high blood pressure). Changes may also be considered due to persistent side effects or intolerance.


Q: Does stress or diet influence the effects of Liza?

The official interaction profile notes that grapefruit or grapefruit juice may increase the amount of medicine in the blood, and official recommendations regarding co-administration should be consulted. However, the medicine is described as being able to be taken with or without food.


Q: What are common misunderstandings about how Liza works?

Official information emphasizes that the primary purpose is to prevent pregnancy by inhibiting the steps necessary for conception. Its method involves actions such as inhibiting ovulation (preventing egg release) and changing the uterine lining.


Q: Why might a person not feel the effects of Liza immediately?

The medicine works through systemic hormonal changes, which require time to establish full contraceptive effectiveness. Official guidance recommends using a back-up method for the first 7 consecutive days of the first cycle to ensure reliable protection.


Q: What kind of monitoring is usually required while using Liza?

According to official warnings, blood pressure should be checked at regular intervals. Specific monitoring of serum potassium is also required for certain high-risk patients who are taking other medications that may raise potassium levels, particularly during the first treatment cycle.


Q: How quickly does Liza typically start working?

Official patient information indicates that the body generally requires at least 7 consecutive days of active pill use before contraception is reliably effective. It is recommended to use an additional form of contraception during this initial 7-day period.


Q: Does Liza affect sleep or energy levels?

Adverse events reported in clinical trials include somnolence (drowsiness) and fatigue (tiredness) with unknown or less common frequency.


Q: Is it normal to feel [minor side effect] when starting Liza?

Official patient guidance notes that it is common to experience unexpected spotting or light bleeding or to feel nauseated during the first 1 to 3 pill packs. These minor effects are typically temporary and often diminish over time as the body adjusts.


Q: Why is Liza sometimes used for conditions other than its main approved use?

In addition to pregnancy prevention, the medicine is officially indicated (approved) for the treatment of symptoms associated with Premenstrual Dysphoric Disorder (PMDD) and for the treatment of moderate acne in women who choose to use it as an oral contraceptive.


Q: Can older adults use Liza safely?

Official warnings state that the medicine must not be used by women over 35 who smoke due to the significantly increased risk of serious cardiovascular events. The medicine is not indicated for use after menopause.


Q: Is it okay to use herbal supplements while taking Liza?

Official labeling advises that some herbal products, such as St. John's Wort, can reduce the effectiveness of the contraceptive pill. It is important that users disclose all medicines and herbal or vitamin products to their healthcare provider.


Q: What happens if I stop taking Liza suddenly?

The primary consequence of discontinuing the active medication is the loss of contraceptive protection. Once active pills are stopped, the possibility of pregnancy returns shortly, and the medicine must be discontinued if pregnancy is suspected.


Q: Are there any known interactions between Liza and alcohol?

The ethinyl estradiol component is noted in drug interaction databases for having a minor interaction with alcohol (ethanol). As with any medication, users should discuss their consumption of alcohol with a healthcare provider.


Q: How does Liza affect my ability to drive or operate machinery?

According to the official product information, the medicine is noted to have no or negligible influence on a user's ability to drive a vehicle or operate machinery.


Q: Are there different brand names for the medicine Liza?

Yes, the active combination of Drospirenone and Ethinyl Estradiol is a generic formulation that is sold under multiple different brand names (e.g., Yasmin, Yaz, Syeda, etc.).


Q: Does Liza have a generic version available?

Yes, the active ingredient combination (Drospirenone and Ethinyl Estradiol) is available in generic versions, in addition to other branded products.


Q: Is it true that Liza can affect mood?

Yes, official adverse reaction reports from clinical trials indicate that mood changes (which may include depressed mood, nervousness, and emotional lability) are reported with common frequency among users.


Q: What is the evidence regarding Liza and weight changes?

Official adverse event reports from clinical trials have noted that both weight gain and weight loss have been reported. These are generally considered uncommon or rare adverse effects.


Q: Does Liza interact with vitamin supplements?

It is important that users disclose all medications, including vitamin and mineral supplements, to their healthcare provider. The ethinyl estradiol component is known to potentially increase the blood levels of caffeine, which may be relevant if consuming caffeine-containing supplements.


Q: How does the effectiveness of Liza change over time?

Clinical studies show that the medication is a highly effective and reliable contraceptive method over long-term use, provided it is taken correctly and consistently every day. Its effectiveness is generally sustained.


Q: Are there specific races or ethnic groups that respond differently to Liza?

Pharmacokinetic studies have specifically examined how the body processes the active ingredients and have noted no clinically relevant differences in the drug's absorption, distribution, metabolism, or excretion between Japanese and Caucasian women.


Q: Are there long-term studies available on the safety of Liza?

Yes, the safety information is supported by data from large, long-term, post-market surveillance cohort studies (such as the EURAS study) that were conducted to compare the cardiovascular and other serious risks of this specific formulation against other types of oral contraceptives.

How should Liza be stored and disposed of?

How to Store and Dispose of Liza (Drospirenone and Ethinyl Estradiol)

Liza tablets must be stored according to specific regulatory requirements to maintain product stability and safety.

Storage Conditions

Detail Requirement
Temperature Range Store at Controlled Room Temperature, between 15 C and 30 C (59 F and 86 F).
Protection Keep away from light, moisture, and excess heat. Do not store in the bathroom.
Container Rule Keep the medication in the original blister pack and container, tightly closed.
Child Safety Must be stored out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Liza should be disposed of via a drug take-back program. If a program is unavailable, do not flush the tablets. Instead, mix the medicine with an unappealing substance, like dirt or used coffee grounds, seal the mixture in a bag, and place it in the household trash. Obscure personal information on the packaging before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Liza found in:

A-Z Index: